Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Silk Road Medical (NASDAQ:SILK) Inc on Tuesday, setting a price target of $75, which is approximately 46.17% above the present share price of $51.31.
Antalffy expects Silk Road Medical Inc to post earnings per share (EPS) of -$0.31 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Silk Road Medical, with an average price target of $68.5.
The analysts price targets range from a high of $75 to a low of $62.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $22.05 million and a net profit of -$10.16 million. The company's market cap is $1.77 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.1% and a 66.67% success rate.
Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. The firm's devices enable vascular access via a puncture adjacent to the collarbone instead of the traditional approach of accessing the vascular system through the groin. Its products include ENROUTE Transcarotid Neuroprotection & Stent System. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.